Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05611931
Title	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)
Acronym	XPORT-EC-042
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Karyopharm Therapeutics Inc
Indications	endometrial adenocarcinoma endometrial serous adenocarcinoma uterine carcinosarcoma
Therapies	Selinexor
Age Groups:	adult \| senior
Covered Countries	USA \| SVK \| ITA \| ISR \| IRL \| HUN \| GRC \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS